AKT1 and prostate carcinoma: Exendin-4 further reverses prostate cancer growth and invasion by counteracting benzalutamide-mediated activation of Akt and mTOR, followed by down-regulation of S6K and 4EBP-1, ultimately reversing the resistance of prostate cancer to benzalutamide.